49645-27-4

Usage

Uses

Used in Peptide and Protein Synthesis:
Z-ASU(OTBU)-OH DCHA is used as a protected amino acid building block for the synthesis of peptide and protein molecules. The protection of the amine and hydroxyl groups by the Z and OTBU groups, respectively, prevents unwanted side reactions during the synthesis process, ensuring the correct formation of peptide bonds and the desired final product.
Used in Organic Chemistry Research:
In the field of organic chemistry, Z-ASU(OTBU)-OH DCHA is used as a versatile intermediate for the synthesis of complex organic molecules. Its protected functional groups allow for selective reactions and the stepwise construction of molecular architectures, facilitating the synthesis of target compounds with high precision and yield.
Used in Medicinal Chemistry Research:
Z-ASU(OTBU)-OH DCHA is employed as a key component in the development of new pharmaceutical agents. Its ability to be incorporated into peptide and protein structures makes it a valuable tool for the design and synthesis of bioactive molecules with potential therapeutic applications. Additionally, its use in organic synthesis can contribute to the discovery of novel drug candidates with unique mechanisms of action.

Upstream product

• 891270-72-7 8-tert-Butyl 1-methyl (2S)-2-{[(benzyloxy)carbonyl]amino}octanedioate 
• 853152-72-4 2-acetylamino-2-ethoxycarbonyl-octanedioic acid 8-tert-butyl ester 1-ethyl ester 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 2492-18-4 tert-butyl hexanoate 
• 19641-64-6 N-(benzyloxycarbonyl)-L-α-aminosuberic acid 
• 115-11-7 isobutene 

Downstream Products

• 104849-05-0 cyclo[2-aminoisobutyryl-(S)-phenylalanyl-(R)-prolyl-(S)-2-aminosuberoyl-] 
• 104849-07-2 (-)-(3S,9S,14aR)-9-benzyl-3-(7-chloro-6-oxoheptyl)-6,6-dimethyldecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone 
• 104849-06-1 (5S,11S,13aR)-5-Benzyl-11-(7-diazo-6-oxo-heptyl)-8,8-dimethyl-decahydro-3a,6,9,12-tetraaza-cyclopentacyclododecene-4,7,10,13-tetraone 
• 104849-04-9 cyclo 
• 104848-88-6 N-(benzyloxycarbonyl)-D-alanyl-L-2-amino-7-(tert-butyloxycarbonyl)heptanoyl-D-proline methyl ester 
• 104849-01-6 N-(benzyloxycarbonyl)-L-2-amino-7-(tert-butyloxycarbonyl)heptanoyl-α-aminoisobutyryl-L-phenylalanyl-D-proline 
• 104849-03-8 L-2-amino-7-(tert-butyloxycarbonyl)heptanoyl-α-aminoisobutyryl-L-phenylalanyl-D-proline acetate salt 
• 70374-95-7 (7S)-7-benzyloxycarbonylamino-7-phenylcarbamoyl-heptanoic acid 
• 329966-99-6 N-benzyloxycarbonyl-ω-t-butyl-(L)-α-aminosuberateanilide 
• 1609191-02-7 (S)-tert-butyl 7-(((benzyloxy)carbonyl)amino)-8-(methoxy(methyl)amino)-8-oxooctanoate 

Relevant academic research and scientific papers

Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure–Activity Relationship, Biostructural, and Kinetic Insight

The sirtuin enzymes are important regulatory deacylases in a variety of biochemical contexts and may therefore be potential therapeutic targets through either activation or inhibition by small molecules. Here, we describe the discovery of the most potent inhibitor of sirtuin 5 (SIRT5) reported to date. We provide rationalization of the mode of binding by solving co-crystal structures of selected inhibitors in complex with both human and zebrafish SIRT5, which provide insight for future optimization of inhibitors with more “drug-like” properties. Importantly, enzyme kinetic evaluation revealed a slow, tight-binding mechanism of inhibition, which is unprecedented for SIRT5. This is important information when applying inhibitors to probe mechanisms in biology.

Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors

The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyr

Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors

The present invention relates to compounds of formula I: or pharmaceutically acceptable salts or tautomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.